



Office of the Vermont Attorney General
109 State Street
Montpelier, VT 05609
Re: New High-Cost Prescription Drugs Reporting

February 22, 2020

Dear Office of the Vermont Attorney General,

In compliance with 18 V.S.A. § 4637, Amneal Pharmaceuticals LLC (“Amneal”) has introduced new generic prescription drugs (“Products”) at a wholesale acquisition cost that is over the threshold set for a specialty drug under the Medicare Part D program, which is attached as Exhibit A. This letter also provides the additional required information by 18 V.S.A. § 4637(c) regarding the Product. Amneal notes that the Office of the Attorney General has not yet prescribed a format for submissions under this section. Further, as authorized by 18 V.S.A. § 4637(d), Amneal has limited the information reported to that which is in the public domain or publicly available.

1. A description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally;
 - › *This drug is a generic product; therefore no marketing and pricing plans are available. This Product is sold in the United States only.*

2. The estimated volume of patients who may be prescribed the drug;
 - › *The estimated average number of patients per month is unknown to Amneal.*

3. Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval;
 - › *Not applicable.*

4. The date and price of acquisition if the drug was not developed by the manufacturer;
 - › *Amneal did not acquire this product.*

Best Regards,

Christopher Slean

Director, Corporate Compliance

EXHIBIT A

NDC	PRODUCT	DATE OF INTRO TO MARKET	WAC
60219172107	Etravirine Tablet 100mg 120	06/14/2021	\$1,287.29
60219172106	Etravirine Tablet 200mg 60	06/14/2021	\$1,287.29